» Articles » PMID: 23694700

Adjusting for Background Mutation Frequency Biases Improves the Identification of Cancer Driver Genes

Overview
Date 2013 May 23
PMID 23694700
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

A common goal of tumor sequencing projects is finding genes whose mutations are selected for during tumor development. This is accomplished by choosing genes that have more non-synonymous mutations than expected from an estimated background mutation frequency. While this background frequency is unknown, it can be estimated using both the observed synonymous mutation frequency and the non-synonymous to synonymous mutation ratio. The synonymous mutation frequency can be determined across all genes or in a gene-specific manner. This choice introduces an interesting trade-off. A gene-specific frequency adjusts for an underlying mutation bias, but is difficult to estimate given missing synonymous mutation counts. Using a genome-wide synonymous frequency is more robust, but is less suited for adjusting biases. Studying four evaluation criteria for identifying genes with high non-synonymous mutation burden (reflecting preferential selection of expressed genes, genes with mutations in conserved bases, genes with many protein interactions, and genes that show loss of heterozygosity), we find that the gene-specific synonymous frequency is superior in the gene expression and protein interaction tests. In conclusion, the use of the gene-specific synonymous mutation frequency is well suited for assessing a gene's non-synonymous mutation burden.

Citing Articles

Pan-cancer clinical impact of latent drivers from double mutations.

Yavuz B, Tsai C, Nussinov R, Tuncbag N Commun Biol. 2023; 6(1):202.

PMID: 36808143 PMC: 9941481. DOI: 10.1038/s42003-023-04519-5.


Untangling a complex web: Computational analyses of tumor molecular profiles to decode driver mechanisms.

Khalighi S, Singh S, Varadan V J Genet Genomics. 2021; 47(10):595-609.

PMID: 33423960 PMC: 7902422. DOI: 10.1016/j.jgg.2020.11.001.


Understanding the impacts of missense mutations on structures and functions of human cancer-related genes: A preliminary computational analysis of the COSMIC Cancer Gene Census.

Malhotra S, Alsulami A, Heiyun Y, Ochoa B, Jubb H, Forbes S PLoS One. 2019; 14(7):e0219935.

PMID: 31323058 PMC: 6641202. DOI: 10.1371/journal.pone.0219935.


Finding driver mutations in cancer: Elucidating the role of background mutational processes.

Brown A, Li M, Goncearenco A, Panchenko A PLoS Comput Biol. 2019; 15(4):e1006981.

PMID: 31034466 PMC: 6508748. DOI: 10.1371/journal.pcbi.1006981.


Overexpressed somatic alleles are enriched in functional elements in Breast Cancer.

Restrepo P, Movassagh M, Alomran N, Miller C, Li M, Trenkov C Sci Rep. 2017; 7(1):8287.

PMID: 28811643 PMC: 5557904. DOI: 10.1038/s41598-017-08416-w.


References
1.
Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

2.
Hodgkinson A, Chen Y, Eyre-Walker A . The large-scale distribution of somatic mutations in cancer genomes. Hum Mutat. 2011; 33(1):136-43. DOI: 10.1002/humu.21616. View

3.
Sherry S, Ward M, Kholodov M, Baker J, Phan L, Smigielski E . dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2000; 29(1):308-11. PMC: 29783. DOI: 10.1093/nar/29.1.308. View

4.
Pleasance E, Cheetham R, Stephens P, McBride D, Humphray S, Greenman C . A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2009; 463(7278):191-6. PMC: 3145108. DOI: 10.1038/nature08658. View

5.
Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S . PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 2010; 23(2):190-200. PMC: 2848976. DOI: 10.1111/j.1755-148X.2010.00685.x. View